Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET AF: Rivaroxaban vs Warfarin in Non-Valvular Atrial Fibrillation
NCT00403767Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2006
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 44
01
Overview
A Phase 3 trial of rivaroxaban in Atrial fibrillation (AFib), sponsored by Johnson & Johnson. Started Dec 2006; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00403767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00403767.